How Compounded Peptides Differ From FDA-Approved Medications

Patients considering peptide therapies frequently encounter marketing language that implies regulatory legitimacy — "pharmaceutical grade," "made in a licensed pharmacy," "manufactured in the USA." Understanding what these terms actually mean, and how they differ from FDA approval, is essential for informed decision-making.

FDA drug approval is a rigorous process that requires a manufacturer to demonstrate, through clinical trials, that a drug is safe and effective for a specific indication in a specific patient population. The process includes:

Preclinical testing: Laboratory and animal studies to assess basic safety and biological activity before human testing begins.

Phase I trials: Small studies (typically 20–80 participants) focused on safety, dosing, and pharmacokinetics in humans.

Phase II trials: Medium-sized studies (typically 100–300 participants) that assess preliminary efficacy and identify optimal dosing.

Phase III trials: Large randomized controlled trials (typically 1,000–3,000 or more participants) that provide definitive evidence of safety and efficacy compared to placebo or existing treatments.

FDA review: The FDA reviews all trial data, manufacturing processes, and labeling before approving the drug for a specific indication.

Post-market surveillance: After approval, the FDA continues to monitor the drug for adverse effects through the MedWatch reporting system and post-market studies.

An FDA-approved drug has been through this entire process. The approval is specific to a particular drug, at a particular dose, for a particular indication. A drug approved for one condition is not automatically approved for another.

Pharmaceutical compounding is the preparation of a customized medication for an individual patient when a commercially available FDA-approved product does not meet that patient's specific needs. Legitimate examples include:

• Preparing a liquid formulation of a drug that is only available as a tablet, for a patient who cannot swallow tablets
• Removing an allergen (such as a dye or preservative) from a commercially available product
• Preparing a topical formulation of a drug that is only available orally

Compounding pharmacies operate under two regulatory frameworks:

503A pharmacies compound medications for individual patients based on a valid prescription. They are regulated primarily by state pharmacy boards, not the FDA. They are not required to demonstrate safety or efficacy for the specific compounded preparation.

503B outsourcing facilities compound in larger batches for healthcare facilities without patient-specific prescriptions. They are subject to FDA oversight and must comply with Current Good Manufacturing Practice (CGMP) standards, but they still do not require FDA approval for the specific compounded preparation.

Domestic manufacture does not confer FDA approval. A compounding pharmacy in the United States can prepare a peptide that has never been through Phase I, II, or III clinical trials, has never been reviewed by the FDA for safety or efficacy, and has no approved indication — and that product can be legally described as "made in a US-licensed pharmacy."

The FDA approves specific drugs for specific indications based on clinical trial data. The location of manufacture is not a factor in the approval decision. A drug manufactured in Germany that has completed the FDA approval process is an FDA-approved drug. A peptide compounded in a US pharmacy that has not completed the approval process is not.

The FDA has raised concerns about the use of compounding to supply peptides that have not been proven safe and effective in humans. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed several peptides — including BPC-157, TB-500, MOTS-C, and others — and considered whether they should be placed on the list of bulk drug substances that cannot be used in compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The FDA's concerns include:

• Lack of human clinical trial data: Most compounded peptides used for musculoskeletal and anti-aging applications have not been studied in large randomized controlled trials in humans.
• Manufacturing quality: Compounded preparations are not subject to the same quality standards as FDA-approved drugs. Purity, potency, and sterility can vary.
• Safety signals: Some peptides have theoretical safety concerns (such as promotion of angiogenesis or cell migration) that have not been adequately evaluated in human studies.

Before receiving any compounded peptide, patients should ask:

1. Is this peptide FDA-approved for this specific indication? If the answer is no, ask what the regulatory status is.
2. What human clinical trial evidence supports its use for my specific condition? Ask for specific citations to peer-reviewed randomized controlled trials, not animal studies or case reports.
3. What compounding pharmacy will prepare this medication? Ask whether the pharmacy is a 503A or 503B facility and whether it has been inspected by the FDA or state pharmacy board.
4. What are the known risks? Ask specifically about the long-term safety profile and any FDA concerns about this compound.
5. What is the prescriber's rationale? A legitimate prescriber should be able to explain the evidence basis and the specific clinical rationale for recommending a compounded peptide over available FDA-approved alternatives.

Patients who cannot get clear answers to these questions should consider seeking a second opinion before proceeding.

References

• U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov, updated 2024.
• U.S. Food and Drug Administration. Human Drug Compounding. 21 CFR Parts 503A and 503B.
• U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. FDA.gov.
• Gudeman J, et al. Potential Risks of Pharmacy Compounding. Drugs R D. 2013;13(1):1–8. DOI: 10.1007/s40268-013-0005-9

Reviewed by Joseph Blythe, DO — July 2026 Last medical review: July 31, 2026

Request an Appointment